Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Faces Scrutiny Amid Insider Confidence

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Faces Scrutiny Amid Insider Confidence

Add to Favorite
Added to Favorite


Leonard Braden Michael, a significant shareholder, purchased 15,209 shares, increasing his stake to 2,757,526 shares, indicating confidence in Adverum’s potential.
Adverum is under investigation by Levi & Korsinsky for potential federal securities law violations related to non-cash accounting errors.
The stock price of NASDAQ:ADVM has seen an 11.23% increase despite the ongoing investigation and planned financial restatements.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a biotechnology company focused on developing gene therapies for ocular and rare diseases. On April 2, 2025, Leonard Braden Michael, a significant shareholder with a 10% stake, purchased 15,209 shares of ADVM at $4.04 each. This acquisition increased his total ownership to 2,757,526 shares, reflecting confidence in the company’s potential.

Despite this insider purchase, Adverum faces scrutiny as Levi & Korsinsky investigates potential federal securities law violations. The company disclosed to the SEC on March 31, 2025, that certain financial statements should not be relied upon due to non-cash accounting errors related to tenant improvement allowances in North Carolina. Consequently, Adverum plans to restate its financials for 2022 and 2023.

The stock price of NASDAQ:ADVM, currently at $4.26, has seen an 11.23% increase, rising by $0.43. Today, the stock fluctuated between $3.87 and $4.39. Over the past year, it reached a high of $14.16 and a low of $3.52. The company’s market capitalization is approximately $88.62 million, with a trading volume of 153,684 shares.

These financial restatements could impact investor confidence and stock performance. However, Leonard Braden Michael’s recent purchase might suggest optimism about Adverum’s future prospects. Investors should monitor the investigation’s outcome and the company’s efforts to address these accounting issues.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Lamb Weston Holdings, Inc. (NYSE:LW) Faces Financial Challenges Amid Market Pressures

The consensus price target for Lamb Weston Holdings, Inc....

UniFirst Corporation (NYSE: UNF) Earnings Overview

UniFirst Corporation (NYSE: UNF) reported an EPS of $1.32,...

Nanobiotix’s Financial and Developmental Update: A Glimpse into the Future

Earnings per share (EPS) of -$0.58, aligning with estimates,...

Tilray Brands, Inc. (NASDAQ:TLRY) Quarterly Earnings Insight

Earnings per Share (EPS) loss of $0.04 anticipated, with...